Epigenomics Wins FDA Approval for Epi proColon

The FDA has approved Epigenomics AG’s colorectal cancer screening blood test Epi proColon, the German-American diagnostics company announced Wednesday.

The test will be made available in the U.S. as part of a joint commercialization agreement with Polymedco.

The test is a noninvasive alternative for patients who would rather not undergo colonoscopies or fecal immunochemical tests. — Anisa Jibrell